參考文獻/References:
[1] Itamochi H, Kigawa J.Molecular targeted therapies for epithe-lial ovarian cancer[J]. Nihon Rinsho,2012, 70(S4): 622-627.
[2] Kroeger P J, Drapkin R.Pathogenesis and heterogeneity of ovarian cancer[J]. Curr Opin Obstet Gynecol,2017, 29(1): 26-34.
[3] Squadrito M L, Baer C, Burdet F, et al.Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells[J]. Cell Rep,2014, 8(5): 1432-1446.
[4] Taylor D D, Gercel-Taylor C.MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer[J]. Gynecol Oncol,2008, 110(1): 13-21.
[5] Deng J L, Xu Y H, Wang G.Identification of Potential Crucial Genes and Key Pathways in Breast Cancer Using Bioinformatic Analysis[J]. Front Genet,2019, 10: 695.
[6] Reczko M, Maragkakis M, Alexiou P, et al.Functional microRNA targets in protein coding sequences[J]. Bioinfor-matics,2012, 28(6): 771-776.
[7] Yi H, Ye J, Yang X M, et al.High-grade ovarian cancer secreting effective exosomes in tumor angiogenesis[J]. Int J Clin Exp Pathol,2015, 8(5): 5062-5070.
[8] Yi H, Zheng X, Song J, et al.Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis[J]. Int J Clin Exp Pathol,2015, 8(12): 15719-15728.
[9] Zeng Z, Li Y, Pan Y, et al.Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis[J]. Nat Commun,2018, 9(1): 5395.
[10] Fong M Y, Zhou W, Liu L, et al.Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis[J]. Nat Cell Biol,2015, 17(2): 183-194.
[11] Ippolito L, Marini A, Cavallini L, et al.Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells[J]. Oncotarget,2016, 7(38): 61890-61904.
[12] Wang Z, Wang J, Yang Y, et al.Loss of has-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer[J]. J Exp Clin Cancer Res,2013, 32: 76.
[13] Guo X, Han T, Hu P, et al.Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention[J]. Int Urol Nephrol,2018, 50(12): 2193-2200.
相似文獻/References:
[1]林文韜 王武煉 肖莉莉 張怡元.基于GEO數(shù)據(jù)庫發(fā)現(xiàn)骨肉瘤關(guān)鍵基因GMFG及其生物學功能[J].福建醫(yī)藥雜志,2020,42(02):112.
LIN Wentao,WANG Wulian,XIAO Lili,et al.Identification of the key gene GMFG and its biological function in osteosarcoma based on GEO database[J].FUJIAN MEDICAL JOURNAL,2020,42(05):112.
[2]鄭金輝,梁瑋,林曉露,等.基于數(shù)據(jù)挖掘分析炭疽毒素受體1在胃癌中的表達及其意義[J].福建醫(yī)藥雜志,2021,43(01):14.
ZHENG Jinhui,LIANG Wei,LIN Xiaolu,et al.Expression of ANTXR1 gene in gastric cancer and its significance based on data mining[J].FUJIAN MEDICAL JOURNAL,2021,43(05):14.
[3]程輝.基于數(shù)據(jù)挖掘分析G蛋白偶聯(lián)受體116在彌漫大B細胞淋巴瘤中的表達及功能預(yù)測[J].福建醫(yī)藥雜志,2021,43(03):22.
CHENG Hui.Analysis of GPR116 expression and function prediction in diffuse large B cell lymphoma based on data mining[J].FUJIAN MEDICAL JOURNAL,2021,43(05):22.
[4]王雪春,徐榕莉,鄭秀瓊.妊娠期糖尿病相關(guān)差異表達基因的生物信息學分析[J].福建醫(yī)藥雜志,2022,44(02):6.
WANG Xuechun,XV Rongli,ZHENG Xiuqiong.Bioinformation analysis of gestational diabetes mellitus-related differentially expressed genes[J].FUJIAN MEDICAL JOURNAL,2022,44(05):6.
[5]吳嘉旭,胡明超,王強,等.NDC1基因在肝癌中的診斷及預(yù)后價值的生物信息學分析[J].福建醫(yī)藥雜志,2023,45(01):7.
WU Jiaxu,HU Mingchao,WANG Qiang,et al.Bioinformatics analysis of the diagnostic and prognostic value of NDC1 gene in liver hepatocellular carcinoma[J].FUJIAN MEDICAL JOURNAL,2023,45(05):7.
[6]沈明虹.上皮性卵巢癌HMGB3表達及預(yù)后價值的生物信息學分析[J].福建醫(yī)藥雜志,2023,45(06):1.
SHEN Minghong.Analysis of HMGB3 expression and prognostic value in epithelial ovarian cancer based on bioinformatics[J].FUJIAN MEDICAL JOURNAL,2023,45(05):1.
[7]蘇川,齊元麟.M2型丙酮酸激酶在宮頸鱗狀細胞癌和宮頸腺癌中臨床意義的生物信息學分析[J].福建醫(yī)藥雜志,2024,46(02):1.[doi:10.20148/j.fmj.2024.02.001]
SU Chuan,QI Yuanlin.Bioinformatics analysis of the clinical significance of PKM2 in cervical squamous cell carcinoma and endocervical adenocarcinoma[J].FUJIAN MEDICAL JOURNAL,2024,46(05):1.[doi:10.20148/j.fmj.2024.02.001]